Translating unique human immune responses into superior medi

Memo Therapeutics AG

Incorporated

20.12.2012

Headquarters

Schlieren

Support

We mine the tumor antibody repertoires of elite cancer patients for the identification of novel antibody-target pairs. These tumor-derived antibodies are then used for the development of targeted cancer therapies.
Our proprietary DROPZYLLA® technology is uniquely suited to mine the antibody repertoires of fragile and short-lived tumor-infiltrating B cells. We screen these repertoires using high-throughput genomic and cell-based assays to identify novel antibodies and their targets. Lead antibodies are then developed either as ADC or T-cell engagers. Our initial focus is on lung, ovarian, and colorectal cancer. Our business model focuses on in-house development until clinical proof of concept (phase Ib/II) and out-licensing of preclinical assets to provide non-dilutive funding.